How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Renal cell carcinoma pathway model report

Closed for comments This consultation ended on at   Request commenting lead permission

2 Recommendations for research

2.1

The committee recommended that future renal cell carcinoma trials should be sufficiently powered to analyse differences in treatment effect by risk group (see section 1.9).

2.2

The committee highlighted areas in the analysis and evidence that could benefit from future research:

  • understanding long-term health-related quality of life in the real world (see section 1.27)

  • survival benefit of immunotherapies in the real world (see section 1.23)

  • understanding how clear and non-clear cell RCC responds to different treatments (see section 1.10)

  • the impact of adjuvant treatment on the effectiveness of advanced treatment (see section 1.11).